摘要
目的:针对2007年2月25日国家食品药品监督管理局下发的、关于修订注射用头孢曲松钠说明书中警示语和注意事项的通知进行释疑。方法:查阅国内外相关文献结合头孢曲松的应用现状进行分析。结果及结论:对头孢曲松钠与含钙制剂为什么不能并用的原因作了阐述,尤其是说明了“本品与含钙剂或含钙产品合并用药有可能导致致死性结局的不良事件”的主要原因,是可诱发以头孢曲松钙为主要成分的胆、肾结石症及相关并发症,且以婴幼儿为多见。只要依据新的说明书使用,头孢曲松钠仍然是安全、有效的药物。
OBJECTIVE：Aim at February 25, 2007 SFDA issued a warning on the revision of cefiriaxone prospectuses. language and elaborate construction of the circular note. METHODS ： Literature both home and abroad concerning pharmacy was reciewed, analyze the application on the combination of ceftriaxone. RESULTS＆CONCLUSION ： Ceftriaxone injection and to emphasize the potential fatal adverse effect while combining with calcium-containing solutions mostly in infant and child. The reason about above official announcement and the interaction mechanisms between ceftriaxone and calcium-containing solution are explained here. Ceftriaxone-associated biliary pseudolithiasis and nephrolithiasis in children are the major problem reported. Ceftriaxone sodium injection still is one of safe and potent antibiotics so far if using it rationally and properly based on the updated labeling.
出处
《中国医院用药评价与分析》
2007年第2期85-88,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
头孢曲松钠
钙剂
配伍问题
用药安全
ceftriaxone sodium
calcium compatibility
compatibility issues
medication safety
